By the end of the day there will likely be more information on what the future of the Johnson & Johnson COVID-19 vaccine in the U.S.
The CDC advisory panel will meet to talk about the blood clot issue, which has been rare in instance- but a big concern for vaccine confidence.
The vaccine has been put on pause in New York and throughout most of the U.S. To date, there have been less than a dozen confirmed cases of this blood clotting issue, which is not yet clearly tied to the vaccine itself.
Officials are hopeful that the vaccine can be used again in the near future.
“No vaccine is perfect, and so ultimately this is going to be a matter of risk, but what I can say is a 95% effective vaccine is extraordinarily effective,” CDC Director Rochelle Walensky said. “If we can have a 95% effective vaccine and we can get our caseloads down, we can be in really good shape as a country.”
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected]